Battle of Thermopylae: 300 Spartans (natural Killer Cells Plus obinutuzumab) Versus the Immortal Warriors (chronic Lymphocytic Leukemia cells) of Xerxes’ Army

García‐Muñoz, Ricardo; Nájera, María-Josefa; Feliu, Jesús; Anton-Remirez, Judith; Ramalle-Gómara, Enrique; Marín-Gorricho, Raquel; Peralta, Raisa; Gutiérrez-Gamarra, Elena; Nuñez-Rodriguez, Jessica; Zafra-Morales, Ricardo; Aguinaga, Lorea; Nebot-Villacampa, María-José; Hernández-Pérez, P.M.; Farfán-Quiroga, Giovanna; Panizo, Carlos; Domínguez‐Garrido, Elena

doi:10.2144/fsoa-2019-0064

Cited by 2 publications

(1 citation statement)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Stimulation with obinutuzumab- or rituximab-coated target cells can induce the expansion of memory-like NK cells [ 232 ]. In patients, obinutuzumab treatment is associated with decreased peripheral NK counts and an increase in the ratio of CD56 bright vs. CD56 dim NK cells [ 85 , 233 , 234 , 235 ]. This decline happens rapidly during the course of the first obinutuzumab infusion, and NK counts remain persistently low between treatments [ 233 ].…”

Section: Effects Of Cll Therapeutics On Nk Functionmentioning

confidence: 99%

Natural Killer Cells in Chronic Lymphocytic Leukemia: Functional Impairment and Therapeutic Potential

Yano

Byrd

Muthusamy

2022

Cancers

View full text Add to dashboard Cite

Immunotherapy approaches have advanced rapidly in recent years. While the greatest therapeutic advances so far have been achieved with T cell therapies such as immune checkpoint blockade and CAR-T, recent advances in NK cell therapy have highlighted the therapeutic potential of these cells. Chronic lymphocytic leukemia (CLL), the most prevalent form of leukemia in Western countries, is a very immunosuppressive disease but still shows significant potential as a target of immunotherapy, including NK-based therapies. In addition to their antileukemia potential, NK cells are important immune effectors in the response to infections, which represent a major clinical concern for CLL patients. Here, we review the interactions between NK cells and CLL, describing functional changes and mechanisms of CLL-induced NK suppression, interactions with current therapeutic options, and the potential for therapeutic benefit using NK cell therapies.

show abstract

Section: Effects Of Cll Therapeutics On Nk Functionmentioning

confidence: 99%

Natural Killer Cells in Chronic Lymphocytic Leukemia: Functional Impairment and Therapeutic Potential

Yano

Byrd

Muthusamy

2022

Cancers

View full text Add to dashboard Cite

show abstract

Serology-based therapeutic strategy in SARS-CoV-2-infected patients

García‐Muñoz

Farfán-Quiroga

Ruiz-de-Lobera

et al. 2021

International Immunopharmacology

Self Cite

View full text Add to dashboard Cite

SARS-CoV-2 infection can be a life-threatening disease. The optimal treatment of patients is not yet standardized. We use a serology-based therapeutic strategy based on the presence of antibodies against the SARS-CoV-2 virus, in which patients with positive serology receive aggressive anti-inflammatory treatment with high-dose dexamethasone and/or tocilizumab and patients with negative serology receive early convalescent plasma therapy. We also analyze the immunological impact of this therapy in the recovery of T cells, B cells and NK cells during hospitalization in a COVID-19 infectious ward. Our results suggest that aggressive therapy with early administration of convalescent plasma and high-dose dexamethasone may be of benefit in patients with SARS-CoV-2 infection and might avoid progression of lung damage or need of admission in intensive care. This strategy did not impair immune responses against SARS-CoV-2, as 93% of the patients generated antibodies against the virus. Independently of previous immunological status of the patients, serology-guided therapy might benefit even patients with a high CIRS-G score, immunosuppressed or medically debilitated individuals and elderly patients. T cell disturbances were most frequent in patients who required high-dose dexamethasone, and B cell depletion was most frequent in patients who received tocilizumab. Early passive immunotherapy with convalescent plasma does not affect lymphoid recovery.

show abstract

Battle of Thermopylae: 300 Spartans (natural Killer Cells Plus obinutuzumab) Versus the Immortal Warriors (chronic Lymphocytic Leukemia cells) of Xerxes’ Army

Cited by 2 publications

References 37 publications

Natural Killer Cells in Chronic Lymphocytic Leukemia: Functional Impairment and Therapeutic Potential

Natural Killer Cells in Chronic Lymphocytic Leukemia: Functional Impairment and Therapeutic Potential

Serology-based therapeutic strategy in SARS-CoV-2-infected patients

Contact Info

Product

Resources

About